Avoid common mistakes on your manuscript.
Paragangliomas are rare tumours that arise within the sympathetic nervous system originating from the neural crest. Nearly 90% of these tumours originate in the medulla of the adrenal glands, and are known as phaeochromocytomas. The remaining 10% are extra-adrenal and are termed paragangliomas. In all, 10% are malignant, and these are often difficult to manage.
The authors discuss the case of a 51-year-old male who presented with biochemical recurrence of a malignant abdominal paraganglioma following surgical excision 4 months previously. CT showed an extensive soft tissue mass enveloping the abdominal aorta (a, solid arrows) and the left ureter, causing hydronephrosis (a, broken arrow). This represented local recurrence of tumour at the excision site. The lesion was inoperable. The tumour did not show affinity to 123I-MIBG (b) or 111In-octreotide (c). An 18FDG-PET scan demonstrated increased metabolic activity within the lesion (d, solid arrows), as well as left-sided hydronephrosis (d, broken arrow). PET imaging with 68Ga-DOTATATE (DOTA-Tyr3-Thr8-octreotide) showed avid tracer uptake within the tumour, indicating positive somatostatin receptor status (e, solid arrows).
123I-MIBG scan is the nuclear medicine imaging method of choice, with a cumulative sensitivity of 86% and specificity of 98% [1]. In neuroendocrine tumours, 68Ga-DOTATOC (DOTA-D-Phe1-Tyr3-octreotide) has been shown to have higher tumour to non-tumour contrast compared with 111In-octreotide [2, 3]. In MIBG-negative cases, imaging with 68Ga-DOTATATE should be considered, especially if the lesion is suspected to be small. Recurrence of malignant paraganglioma is often difficult to manage, especially if the tumour is MIBG receptor negative and is not amenable to surgery. In this challenging group, positive imaging with 68Ga-DOTATATE carries the opportunity of targeted radionuclide therapy with suitable beta emitters such as 90Y-DOTATATE [4].
References
Ell PJ, Gambhir SS. Nuclear medicine in clinical diagnoses and treatment. 3rd ed. New York: Churchill Livingstone; 2004
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8
Lewington V. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003;10(4):497–501
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Win, Z., Rahman, L., Murrell, J. et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 33, 506 (2006). https://doi.org/10.1007/s00259-005-0035-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-0035-9